The cancer therapeutics market size is expected to reach US$ 5,31,538.02 million by 2031 from US$ 2,30,423.56 million in 2024. The market is estimated to record a CAGR of 12.8% from 2025 to 2031.
Executive Summary and Global Market Analysis
Propelled by the rising incidence of breast and lung cancers and substantial investments in R&D, the global cancer therapeutics market is on a path of steady growth. The field of cancer therapeutics is incredibly diverse, encompassing a variety of treatments from chemotherapy and radiation therapy to modern immunotherapy and targeted and hormone therapies. The central aim of all these strategies is the same: to defeat cancer cells, alleviate patient symptoms, and ultimately improve both survival and quality of life. Treatment is rarely one-size-fits-all; it's a personalized approach that often combines multiple therapies tailored to the specific type and stage of cancer, as well as the patient’s overall health.
Cancer Therapeutics Market Segmentation Analysis
The cancer therapeutics market can be effectively segmented in three crucial ways: by therapy type, indication, and distribution channel. In the therapy type category, the market is broken down into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other approaches, with chemotherapy having the largest market share in 2024. By indication, the market addresses blood cancer, lung cancer, breast cancer, colorectal cancer, and other specific conditions. Of these, lung cancer represented the biggest share in 2024. Lastly, the distribution channels include hospital pharmacies, retail pharmacies, and online stores. Hospital pharmacies maintained the largest share of the market in 2024.
Cancer Therapeutics Market Drivers and Opportunities
The enormous global burden of cancer acts as a primary market driver. The World Health Organization reports that approximately one in six deaths globally is due to cancer. With an estimated 20 million new cancer diagnoses in 2022, this number is projected to skyrocket by 77% by 2050, which will significantly challenge healthcare systems worldwide. Genetic factors also play a role; the American Cancer Society notes that 5–10% of all cancers are inherited. Mutations in hereditary cancer susceptibility genes like BRCA1 and BRCA2 are known to greatly increase the risk of developing cancers such as breast, ovarian, and prostate. Globally, breast cancer is the most prevalent cancer among women, with its incidence rising due to environmental exposure, genetic susceptibility, and lifestyle choices.
Download our Sample PDF Report
@ https://www.businessmarketinsights.com/sample/BMIRE00031299
Cancer Therapeutics Market Size and Share Analysis
When we look at the market by therapy type, it's segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment held the dominant market position in 2024. Chemotherapy agents are effective because their cytotoxic action halts or slows the proliferation of cancer cells. These drugs are delivered systemically through the bloodstream, allowing them to target and disrupt cancer cell growth throughout the body. The National Institutes of Health estimates that around 650,000 cancer patients in the U.S. undergo chemotherapy annually. In terms of indications, the lung cancer segment commanded the largest share of the market in 2024.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications